A
Akmal Safwat
Researcher at Aarhus University Hospital
Publications - 101
Citations - 4865
Akmal Safwat is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Sarcoma & Total body irradiation. The author has an hindex of 22, co-authored 90 publications receiving 3565 citations. Previous affiliations of Akmal Safwat include Northwood University & Al-Azhar University.
Papers
More filters
Journal ArticleDOI
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,Silvia Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,Piero Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,P. Dileo,Mikael Eriksson,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,Silvia Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,R. L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf-Dieter Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Pantaleo,R. Piana,Piero Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,Kirsten Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
TL;DR: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal; University HospitalEssen, Essen, Germany; Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome.
Journal ArticleDOI
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,A. Fedenko,Virginia Ferraresi,Andrea Ferrari,S. Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,P. Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,E. Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
TL;DR: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal; University Hospital Essen, Essen Germany; Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy.
Journal ArticleDOI
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali,Stefan S. Bielack,N. Abecassis,Hannu T. Aro,Sebastian Bauer,R. Biagini,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Bernadette Brennan,Thomas Brodowicz,Javier Martin Broto,Laurence Brugières,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Catharina Dhooge,Mikael Eriksson,Franca Fagioli,Alexander Fedenko,Virginia Ferraresi,Andrea Ferrari,S. Ferrari,A.M. Frezza,Nathalie Gaspar,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,B. Hassan,Stefanie Hecker-Nolting,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Leo Kager,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,Ruth Ladenstein,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Bruce Morland,Maria Abbondanza Pantaleo,R. Piana,P. Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,Sandra J. Strauss,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,W.T.A. van der Graaf,W.T.A. van der Graaf,Jeremy Whelan,Eva Wardelmann,Olga Zaikova,Jean-Yves Blay +74 more
TL;DR: Primary bone tumours are rare, accounting for < 0.2% of malignant neoplasms registered in the EUROCARE (European Cancer Registry based study on survival and care of cancer patients) database, and different bone tumour subtypes have distinct patterns of incidence.
Journal ArticleDOI
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa Marina,Sigbjørn Smeland,Stefan S. Bielack,Mark L. Bernstein,Gordana Jovic,Mark Krailo,Jane Hook,Jane Hook,Carola A.S. Arndt,Henk van den Berg,Bernadette Brennan,Bénédicte Brichard,Kenneth L.B. Brown,Trude Butterfass-Bahloul,Gabriele Calaminus,Heike E. Daldrup-Link,Mikael Eriksson,Mark C. Gebhardt,Hans Gelderblom,Joachim Gerss,Robert E. Goldsby,Allen M. Goorin,Richard Gorlick,Holcombe E. Grier,Juliet Hale,Kirsten Sundby Hall,Jendrik Hardes,Douglas S. Hawkins,Knut Helmke,Pancras C.W. Hogendoorn,Michael S. Isakoff,Katherine A. Janeway,Heribert Jürgens,Leo Kager,Thomas Kühne,Ching C. Lau,Patrick J. Leavey,Stephen L. Lessnick,Leo Mascarenhas,Paul A. Meyers,Hubert Mottl,Michaela Nathrath,Zsuzsanna Papai,R. Lor Randall,Peter Reichardt,Marleen Renard,Akmal Safwat,Cindy L. Schwartz,Michael C. Stevens,Sandra J. Strauss,Lisa A. Teot,Mathias Werner,Matthew R. Sydes,Jeremy Whelan +53 more
TL;DR: The EURAMOS-1 results do not support the addition of ifosfamide and etoposide in patients with poorly responding osteosarcoma, and the primary outcome measure was event-free survival measured in the intention-to-treat population.